Dr. Philippe Gadal, a director nominee, currently serves as a regulatory advisor for various companies, including bioMérieux Inc., Rapid Micro Biosystems Inc, and Microbs SAS, since September 2020. From January 2017 to June 2020, Dr. Gadal served as the General Manager of Hyglos, a company purchased by bioMérieux SA. He served on the board and as chairman of the audit committee and compensation committee of ERBA Diagnostics, Inc. from September 2010 to December 2016. From 2009 to 2012, Dr. Gadal served as the Chief Executive Officer of AES Chemunex Inc., a manufacturer and developer of tests, equipment and reagents for microbiological laboratories. From 2003 through 2008, he served as the Chief Executive Officer of Trinity Biotech USA, the United States subsidiary of Trinity Biotech PLC, an international diagnostics company. Prior to joining Trinity Biotech, Dr. Gadal served in a variety of positions for companies involved in the in vitro diagnostics industry, including General Manager of Diagnostica Stago Inc., a private medical devices company, from 1995 through 2003; Director of Hematology for Roche Diagnostics, a subsidiary of Hoffmann-La Roche Ltd., a leading company in the field of pharmaceutical and diagnostics, from 1993 through 1995; Director of the Hematology Business Unit for ABX France, a subsidiary of Hoffman-La Roche, from 1991 through 1992; and President of ABX USA, a medical devices company which specializes in hematology. He received a Doctorate of Pharmacy (Pharm D) from Paul Sabatier University in France. We believe that Dr. Gadal’s vast experience as an executive officer of companies within the life sciences industry qualify him to serve as a member of our board of directors.